Carvolix

Carvolix EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Carvolix (CVX.PA) as of Nov 2, 2026 is -18.82. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -18.14 — a change of 3.75% (lower).

EV/FCF

-18.82

YoY

3.75%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Carvolix is 2025 -18.82 . EV/FCF (Enterprise Value to Free Cash Flow) of Carvolix was 2024 -18.14 . It decreases by 3.75% lower compared to the previous year.

The Carvolix EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-17.68 EUR
Jan 1, 2019
-18.99 EUR
Jan 1, 2020
-23.11 EUR
Jan 1, 2021
-16.28 EUR
Jan 1, 2022
-19.02 EUR
Jan 1, 2023
-17.48 EUR
Jan 1, 2024
-18.14 EUR
Jan 1, 2025
-18.82 EUR
The Carvolix EV/FCF history
YEAREV/FCFYoY
-18.82+3.75%
-18.14+3.81%
-17.48-8.12%
-19.02+16.83%
-16.28-29.55%
-23.11+21.68%
-18.99+7.40%
-17.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carvolix Stock analysis

What does Carvolix do? Affluent Medical SA develops minimally invasive prostheses that mimic human anatomy and restore native physiology for cardiovascular and urological therapies. The company offers products including Kalios, Epygon, and Artus, targeting heart disease and urinary incontinence treatments. These solutions utilize transcatheter and flow control technologies with optimized, biocompatible components designed for minimally invasive implant procedures. The company's products are sold to healthcare providers and medical institutions seeking advanced solutions for critical conditions. Affluent Medical SA focuses on treating serious and widespread diseases through innovative implantable technologies that replicate natural bodily functions without extensive surgical intervention. With a workforce of 54 full-time employees based in Aix-En-Provence, Paca, the company delivers specialized medical devices that address unmet needs in cardiovascular and urological care. Its product portfolio targets high-value clinical segments where minimally invasive approaches improve patient outcomes and reduce recovery times. Carvolix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Carvolix stock

EV/FCF (Enterprise Value to Free Cash Flow) of Carvolix is -18.82 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Carvolix changed from -18.14 to -18.82, representing a 3.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Carvolix since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Carvolix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Carvolix

All Key Metrics — Carvolix